9 results about "Prothrombin time" patented technology

The invention belongs to the technical field of polypeptide preparation and biological pharmacy, and particularly relates to eggshell membrane polypeptide with thrombin inhibition activity and application of the eggshell membrane polypeptide. According to the invention, two polypeptides are separated and purified from an eggshell membrane, and the two polypeptides are a nonapeptide YDGQHGRVS and an octapeptide EVPPSAL respectively. Tests prove that the nonapeptide YDGQHGRVS and the octapeptide EVPPSAL have thrombin inhibition activity equivalent to that of positive control heparin sodium, and discover that the nonapeptide YDGQHGRVS prolongs the activated partial thromboplastin time and the prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSAL provided by the invention are derived from eggshell membranes, are natural in source, good in thrombin inhibition activity and high in safety, and have a good application prospect.

A fully-printed sensor chip for measuring prothrombin time of a blood sample. The sensor chip includes a pair of electrodes and a pair of contact pads, each electrically coupled to a different one of the electrodes, printed on the surface of the substrate using conductive ink materials. When a blood sample is placed on the sample chip in contact with both electrodes, an impedance of the blood sample is determined based on a measured impedance between the two contact pads. As the blood sample clots, the impedance value changes and the prothrombin time for the blood sample is determined based on a measurement time of a maximum impedance value. A resistive bridge printed on the substrate surface between the contact pads increases a baseline measurement for the sensor chip to a value within a range that is measurable by lower-cost measurement equipment.

The present application belongs to the technical field of polypeptide preparation and biopharmacy, and particularly relates to eggshell membrane polypeptides with thrombin inhibitory activity and application thereof. Two polypeptides are obtained by separation and purification from eggshell membranes, which are nonapeptide YDGQHGRVS and octapeptide EVPPSPAL. It is proved by experiments that the nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL have thrombin inhibitory activity equivalent to that of the positive control heparin sodium, and it is found that the nonapeptide YDGQHGRVS prolongs activated partial thromboplastin time and prothrombin time. The nonapeptide YDGQHGRVS and the octapeptide EVPPSPAL provided by the present application are derived from eggshell membranes, are natural in origin, have good thrombin inhibitory activity, high safety, and have good application prospect.

The invention belongs to biomedical materials, and particularly relates to an antibacterial and anticoagulant coating material for a blood contact material and application of the antibacterial and anticoagulant coating material. The antibacterial and anticoagulant coating material comprises copper tetracarboxyl phenyl porphyrin loaded with an anticoagulant and water-soluble polysaccharide. A coating formed on the basis of the antibacterial and anticoagulant coating material can achieve antibacterial and anticoagulant effects at the same time, for example, the bacteriostasis rate on escherichia coli and the bacteriostasis rate on staphylococcus epidermidis can reach 90%; in addition, the activated part thromboplastin time, prothrombin time and thrombin time of the coating are obviously higher than those of an untreated blood contact material; and the hemolysis rate is lower than 5%.

The invention discloses an in-vitro sample detection data-based decompensated liver cirrhosis risk assessment method and a related device, and relates to the technical field of liver cirrhosis condition assessment. The method comprises the following steps: acquiring in-vitro detection sample data corresponding to a to-be-assessed blood sample, the in-vitro detection sample data comprises sCD146, prothrombin time, serum albumin and platelet count; performing data preprocessing on the in-vitro detection sample data, namely generating a serum albumin grade variable ALBgrade based on a preset grading threshold value according to the numerical value of the serum albumin; inputting the processed feature data into a pre-trained binary Logistic regression model, and outputting a decompensated liver cirrhosis risk value corresponding to the to-be-evaluated blood sample; the decompensated liver cirrhosis risk value is a prediction probability P output by the binary Logistic regression model. The method can effectively improve the evaluation accuracy of decompensated liver cirrhosis.

The invention discloses an extraction and separation method of anise polysaccharide with anticoagulant activity. The method comprises the following steps: crushing fresh anise, extracting with hot water, concentrating a water extract, and adding ethanol for precipitation to obtain crude polysaccharide; removing protein by adopting a Sevage method; and dialyzing to remove small molecular impurities, and freeze-drying to obtain the purified anise polysaccharide. The molecular weight of the polysaccharide is about 72.053 kDa. In-vitro coagulation experiments show that the polysaccharide can significantly prolong prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) and reduce the content of fibroblast egg (FIB) white, and shows significant anticoagulant activity. The star anise polysaccharide provided by the invention can be used for preparing anticoagulant drugs, and has the advantages of wide raw material source, simple extraction process, definite activity and the like.

The invention discloses a method for predicting the lactic acid rise risk of a patient with sepsis with acute lung injury, and the method is to construct a model for predicting the lactic acid rise risk of the patient with sepsis with acute lung injury, and the model comprises the following indexes: chronic obstructive pulmonary disease, anion gap (AG), artery pH and prothrombin time (PT). The prediction method provided by the invention has relatively good distinction degree and accuracy for predicting the lactic acid rise risk of the sepsis with acute lung injury ICU patient, has relatively high practicability and applicability clinically, and is helpful for a clinician to early identify the sepsis with acute lung injury ICU patient with high risk of lactic acid rise; corresponding means are timely adopted for treatment intervention, so that the pain of the patient is relieved, the life quality of the patient is improved, and the application prospect is wide.

This invention discloses the application of sodium thiocyanate in the preparation of a kit for coagulation assays. The kit detects coagulation parameters based on coagulation methods, chromogenic substrate methods, or immunoturbidimetric assays. These coagulation parameters include prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen, fibrin(ogen) degradation products, D-dimer, antithrombin III, and anti-Xa. By adding sodium thiocyanate to the coagulation assay kit, this invention optimizes the clinical relevance of the assay kit by adjusting reaction time (coagulation method), improving the linear range (chromogenic substrate method), and enhancing the differentiation between low and high values ​​(immunoturbidimetric assay), thereby improving the accuracy of the test.

The invention discloses a model for early prediction of acute kidney injury risk after a sepsis patient is transferred into ICU based on clinical variables and immune inflammation indicators, and an immune-clinical model is established by adopting an XGBoost algorithm based on data of 1551 domestic sepsis patients in 24 hours after the sepsis patient is transferred into the ICU so as to predict the risk of SA-AKI of the patient. The model integrates five clinical variables including procalcitonin, APACHE II, SOFA score, gender and prothrombin time and four immune inflammation indexes including IgA, complement C3, Nave CD4 + T% and CD28 + CD4 + T%, the average ROC-AUC value is 0.914, an SHAP method is introduced to generate a feature importance map and an individual prediction interpretation map, the contribution degree of each index to risk prediction of a specific patient can be visually displayed, the cause of SA-AKI of the patient can be explained, and the risk of the specific patient can be predicted. Therefore, doctors can take targeted measures preventively.